Search results for "interleukin-2"

showing 10 items of 269 documents

DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients.

2011

Recent studies show that regulatory T cells (Tregs) play an essential role in tolerance induction after organ transplantation. In order to examine whether there are differences in the composition of the total CD4(+)CD127(low+/-)FoxP3(+)- Treg cell pool between stable transplant patients and patients with biopsy proven rejection (BPR), we compared the percentages and the functional activity of the different Treg cell subsets (DR(high+)CD45RA(-)-Tregs, DR(low+)CD45RA(-)-Tregs, DR(-)CD45RA(-)-Tregs, DR(-)CD45RA(+)-Tregs). All parameters were determined during the three different periods of time after transplantation (0-30 days, 31-1,000 days, >1,000 days). Among 156 transplant patients, 37 pat…

AdultGraft Rejectionmedicine.medical_specialtymedicine.drug_classClinical Research DesignImmune Cellslcsh:Medicinechemical and pharmacologic phenomenaMonoclonal antibodyT-Lymphocytes RegulatoryOrgan transplantationInterleukin-7 Receptor alpha SubunitYoung AdultT-Lymphocyte SubsetsBiopsymedicineHumanslcsh:ScienceKidney transplantationAgedKidneyMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RInterleukin-2 Receptor alpha Subunithemic and immune systemsForkhead Transcription FactorsHLA-DR AntigensMiddle AgedImmunologic Subspecialtiesmedicine.diseaseKidney TransplantationTransplant rejectionTransplantationTolerance inductionmedicine.anatomical_structureNephrologyImmunologyLeukocyte Common AntigensMedicinelcsh:QClinical ImmunologySurgerybusinessResearch ArticlePloS one
researchProduct

Effect of cordycepin on interleukin-10 production of human peripheral blood mononuclear cells

2002

Therapeutic options for controlling autoimmune diseases are still very limited. Interleukin-10 has been reported to be a promising approach to therapeutic intervention. In the search for a drug which results in the selective upregulation of interleukin-10, we investigated the immunoregulative effects of cordycepin. We have measured interleukin-10 and interleukin-2 secretion of human peripheral blood mononuclear cells that were incubated with cordycepin and assessed the influence of cordycepin on the expression of interleukin-10 mRNA, the proliferative response and the expression of surface markers on T lymphocytes. In addition, the subsets of interleukin-10-secreting cells, the influence of…

AdultInterleukin 2T-Lymphocytesmedicine.medical_treatmentPharmacologyBiologyLymphocyte ActivationPeripheral blood mononuclear cellchemistry.chemical_compoundAdjuvants ImmunologicAntigens CDmedicineHumansRNA MessengerIL-2 receptorCells CulturedPharmacologyDeoxyadenosinesDose-Response Relationship DrugCordycepinMonocyteInterleukinFlow CytometryInterleukin-10Up-RegulationInterleukin 10medicine.anatomical_structureCytokinechemistryImmunologyLeukocytes MononuclearInterleukin-2Cell Divisionmedicine.drugEuropean Journal of Pharmacology
researchProduct

Correlation of Clinical and Immunologic Parameters of the Inflammatory Activity of Pulmonary Sarcoidosis

1991

The evaluation of activation markers such as T4/T8 ratio and HLA-DR expression of lymphocytes of bronchoalveolar lavage (L-BAL) is an important clinical approach for the staging of sarcoidosis. However, it is not known to what extent this is paralleled by an exaggerated lymphocyte function. We investigated the dependence of L-BAL activation markers on the production of interleukin-2 (IL-2) by L-BAL and on the soluble IL-2 receptor serum level (sIL-2R) in 116 patients with sarcoidosis. In none of the combinations tested was a correlation between the two groups of parameters found; r less than 0.5, upper 90% confidence limit of r less than 0.8. Interestingly, IL-2 production is independent of…

AdultLung DiseasesMalePulmonary and Respiratory MedicineSystemic diseaseSarcoidosisT-LymphocytesLymphocyteCD4-CD8 RatioCD4-CD8 RatioEnzyme-Linked Immunosorbent AssayInflammationLymphocyte ActivationHumansMedicineReceptormedicine.diagnostic_testbusiness.industryRespiratory diseaseReceptors Interleukin-2HLA-DR Antigensrespiratory systemmedicine.diseaserespiratory tract diseasesBronchoalveolar lavagemedicine.anatomical_structureImmunologyInterleukin-2FemaleSarcoidosismedicine.symptombusinessBronchoalveolar Lavage FluidAmerican Review of Respiratory Disease
researchProduct

Proinflammatory CX3CR1+CD59+Tumor Necrosis Factor–Like Molecule 1A+Interleukin‐23+ Monocytes Are Expanded in Patients With Ankylosing Spondylitis and…

2018

Objective: Gut-derived innate lymphoid cell 3 (ILC3) has been shown to participate in the pathogenesis of ankylosing spondylitis (AS). CX3CR1+ mononuclear phagocytes (MNPs) have been demonstrated to modulate ILC3 function in the gut. This study was undertaken to investigate the role of proinflammatory CX3CR1+CD59+ MNPs in modulating ILC3 function in AS patients. Methods: MNP subsets in the blood of AS patients and controls were analyzed by flow cytometry. The presence of CX3CR1+CD59+ cells in tissue was confirmed by confocal microscopy. Expression of the proinflammatory chemokines CX3CL1 and CCL2 and decoy receptor 6 (DcR-6) was analyzed. Peripheral CX3CR1+CD59+ cells were cocultured with I…

AdultMale0301 basic medicineChemokineImmunologyPopulationCX3C Chemokine Receptor 1CD11cCD59 Antigenschemical and pharmacologic phenomenaCCL2Interleukin-23MonocytesProinflammatory cytokineFlow cytometry03 medical and health sciences0302 clinical medicineRheumatologymedicineHumansImmunology and AllergySpondylitis AnkylosingLymphocytesCX3CL1educationMononuclear Phagocyte System030203 arthritis & rheumatologyeducation.field_of_studybiologymedicine.diagnostic_testChemistryInnate lymphoid cellMiddle AgedImmunity Innate030104 developmental biologyReceptors Tumor Necrosis Factor Type ICase-Control Studiesbiology.proteinCancer researchFemaleArthritis & Rheumatology
researchProduct

Both IL-12p70 and IL-23 are synthesized during active Crohnʼs disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody

2005

Background: Interleukin (IL)-12p70 and IL-23 are key T helper-1 (TH1) cytokines that drive the inflammation seen in numerous models of intestinal inflammation. These molecules contain an identical p40 chain that is bound to a p35 chain in IL-12 and a p19 chain in IL-23, making both potentially susceptible to modulation by an anti-IL-12p40 monoclonal antibody (mAb). Methods: In the present study, we sought to determine whether active inflammation in Crohn's disease (CD) is associated with the increased synthesis of both of these cytokines and whether patients treated with an anti-IL-12p40 mAb down-regulate IL-23 as well as IL-12p70 as previous reported. Results: To this end we initially dete…

AdultMaleAdolescentBiopsyT-Lymphocytesmedicine.medical_treatmentT cellDown-RegulationInterleukin-23Crohn DiseaseInterleukin 23medicineHumansImmunology and AllergyCells CulturedAgedLamina propriaMucous MembraneCD40biologyInterleukin-12 Subunit p40Interleukin-6InterleukinsMacrophagesGastroenterologyAntibodies MonoclonalInterleukinMiddle AgedInterleukin-12Protein Subunitsmedicine.anatomical_structureCytokineImmunologyInterleukin-23 Subunit p19biology.proteinInterleukin 12FemaleTumor necrosis factor alphaInterleukin-1Inflammatory Bowel Diseases
researchProduct

T cells involved in psoriasis vulgaris belong to the Th1 subset

1994

Although the pathogenesis of psoriasis vulgaris is still unknown, several characteristics point to an immunologically mediated process. Epidermal psoriatic lesions are characterized by a hyperproliferation of keratinocytes and an infiltration of T lymphocytes and granulocytes. Because the former may be mediated in part by lymphokines secreted by T cells, we have focused our interest on the in vivo and in vitro cytokine secretion patterns of T lymphocytes from psoriatic lesions. In five patients T lymphocytes were obtained from epidermal specimens. The cells were propagated with lectin and irradiated feeder cells and subsequently cloned by limiting dilution. The resulting T-cell clones were …

AdultMaleBiopsyCD8 AntigensT-Lymphocytesmedicine.medical_treatmentMolecular Sequence DataDermatologyBiologyPolymerase Chain ReactionBiochemistryInterferon-gammaT-Lymphocyte SubsetsPsoriasisSynovial FluidmedicineHumansPsoriasisRNA MessengerMolecular BiologyCells CulturedAgedSkinAged 80 and overBase SequenceTumor Necrosis Factor-alphaArthritis PsoriaticLymphokineInterleukinT-Lymphocytes Helper-InducerCell BiologyT lymphocyteMiddle Agedmedicine.diseaseInterleukin-10PhenotypeCytokineepidermal T cellsCD4 AntigensImmunologyCytokinesInterleukin-2cytokine productionFemaleCytokine secretionTumor necrosis factor alphaInterleukin-4CD8
researchProduct

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

2012

Abstract Background EMD 521873 (Selectikine), an immunocytokine comprising a DNA-targeting antibody, aimed at tumour necrosis, fused with a genetically modified interleukin-2 (IL-2) moiety, was investigated in this first-in-human phase I study. Methods Patients had metastatic or locally advanced solid tumours failing previous standard therapy. Selectikine was administered as a 1-hour intravenous infusion on 3 consecutive days, every 3weeks. A subgroup of patients also received 300mg/m 2 cyclophosphamide on day 1 of each cycle. Escalating doses of Selectikine were investigated with the primary objective of determining the maximum tolerated dose (MTD). Results Thirty-nine patients were treate…

AdultMaleCancer Researchmedicine.medical_specialtyNecrosisCyclophosphamideMaximum Tolerated DoseLymphocyteRecombinant Fusion ProteinsSelectikineAntineoplastic AgentsPharmacologyGastroenterologyEMD 521873Young AdultPhase IDose-escalationInternal medicineNeoplasmsmedicineHumansAgedbiologyDose-Response Relationship Drugbusiness.industryEosinophilMiddle AgedRashAdvanced solid tumoursmedicine.anatomical_structureOncologyToxicitybiology.proteinInterleukin-2SelectikineFemalemedicine.symptomAntibodybusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct

Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.

1993

Abstract The haplotype HLA-B8,DR3 is over-represented in several autoimmune diseases, implying that genes predisposing people to these disorders are linked to this haplotype. In these diseases, various dysfunctions reflecting an impairment of the immune system have been found. Several reports indicate also that in HLA-B8,DR3-positive healthy subjects similar disorders may be demonstrated. In the present work, we have evaluated NK and LAK activity in these subjects. The study has been performed on monocyte-depleted peripheral blood MNCs by using the K-562 cell line as a target for NK activity and the HL-60 cell line for as a target LAK activity. LAK cells were obtained by incubating MNCs for…

AdultMaleImmunologyFluorescent Antibody TechniqueBiologyCD16Natural killer cellHLA-B8 AntigenImmune systemHLA-DR3 AntigenmedicineTumor Cells CulturedImmunology and AllergyHumansCytotoxicityKiller Cells Lymphokine-ActivatedLymphokine-activated killer cellHaplotypeReceptors IgGLymphokineGeneral MedicineCytotoxicity Tests ImmunologicKiller Cells Naturalmedicine.anatomical_structureHaplotypesCell cultureImmunologyInterleukin-2FemaleHuman immunology
researchProduct

In vitro treatment with interleukin-2 normalizes type-1 cytokine production by lymphocytes from elderly

2000

The term immunosenescence is taken to mean the deterioration of immune function seen in elderly, which is manifested in increased susceptibility to infectious diseases, neoplasias, and autoimmune diseases. It is only recently that we have begun to understand the cellular and molecular changes involved. Of special interest in this regard are observations of a decline in synthesis of Type-1 cytokines which predisposes to diminished cell mediated immunity. We have evaluated the production of type 1 cytokines in old and young donors either in presence or in absence of recombinant interleukin-2 (rIL-2). Lymphocytes were stimulated with plastic bound anti-CD3 and after 48 h the supernatants were …

AdultMaleInterleukin 2Agingmedicine.medical_specialtymedicine.medical_treatmentImmunologyIn Vitro TechniquesBiologyToxicologylaw.inventionInterferon-gammaImmune systemlawInternal medicinemedicineHumansImmunology and AllergyAgedAged 80 and overPharmacologyGeneral MedicineImmunosenescenceMiddle AgedTh1 CellsInterleukin-12Recombinant ProteinsCell mediated immunityIn vitroEndocrinologyCytokineImmunologyRecombinant DNACytokinesInterleukin-2Femalemedicine.drug
researchProduct